Opeolu Makanju Adeoye, MD, MS, FACEP, FAHA
Photo: Opeolu Adeoye



Elected 2022

I have extensive clinical trial experience. I am Lead and Administrative PI of the Phase 3 Multi-arm Optimization of Stroke Thrombolysis (MOST) Trial that is the collaborative culmination of the CLEAR Trials, for which I was also PI. I serve as Multiple PI of the University of Cincinnati Hub Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN), previously serving as Contact PI prior to my recent move to Washington University in Saint Louis.

My primary area of clinical research interest is in developing and testing novel antithrombotic approaches to the treatment of acute ischemic stroke. I previously conducted Phase 2 clinical trials (the CLEAR trials) testing eptifibatide, a glycoprotein 2b/3a inhibitor, as an adjunct to thrombolysis in ischemic stroke. That work led to the ongoing Phase 3 MOST trial. This interest has also led to my conducting translational research using high throughput “omics” techniques to pursue diagnostic and prognostic markers for both ischemic and hemorrhagic stroke. In the near term, I hope to expound on this work to identify pathways that may contribute to stroke outcomes and response to treatment in order to develop new treatments for stroke.

Honors / awards

National Academy of Medicine (2022)